Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine

Zakaria A. Almsherqi, Craig S. McLachlan, Peter Mossop, Yuru Deng

Research output: Contribution to journalArticle

6 Citations (Scopus)


Antiplatelet treatment for patients undergoing percutaneous coronary interventions is a rapidly changing area. Thienopyridines derivatives (ticlopidine and clopidogrel) have shown to decrease major cardiovascular events. Ticlopidine can cause rare but serious side effects, especially during the first 3 months of treatment. Clopidogrel appears to be a safer alternative to ticlopidine. However, resistance to clopidogrel therapy may increases the risk of recurrent cardiovascular events. Whether increased doses of clopidogrel might overcome this resistance in nonresponsive patients warrants further investigation.

Original languageEnglish
Pages (from-to)101-102
Number of pages2
JournalInternational Journal of Cardiology
Issue number1
Publication statusPublished - 2 Jan 2007
Externally publishedYes



  • Antiplatelet treatment
  • Clopidogrel
  • Percutaneous coronary intervention
  • Ticlopidine

Cite this